Allergy Research Group, Pregnenolone 50 mg 60 Scored Tablets
Micronized pregnenolone to support cognitive function, mood, stress resilience, and healthy hormone synthesis.*
Pregnenolone 50 mg is a micronized, bioavailable form of this neurosteroid and hormone precursor to support mood, stress resilience, and the synthesis of key hormones like cortisol, progesterone, and estrogen.*
What It Does
Pregnenolone is a neurosteroid and hormone precursor that plays a vital role in the production of cortisol, progesterone, estrogen, testosterone, and other steroid hormones.* It may support mood, focus, and the body’s adaptive response to stress as levels decline with age.*
How It Works
Pregnenolone (Micronized): A bioavailable form of the parent steroid hormone that supports adrenal, reproductive, and neurological function.*[1]
Neurosteroid Activity: Synthesized in the brain and peripheral nervous system, pregnenolone modulates GABA and NMDA receptors and influences neuroplasticity via BDNF.*[2,3,4,5]
Hormone Precursor: Serves as the first step in the synthesis of key hormones, including cortisol and sex hormones, influencing metabolism, immune balance, and reproductive health.*[1,6]
Cognitive and Mood Support: Clinical trials suggest pregnenolone supplementation supports focus, working memory, and mood, particularly in populations under cognitive or emotional strain.*[7,8,9]
Age-Related Optimization: Endogenous pregnenolone production decreases with age. Pregnenolone supports mental stamina and resilience.*[6,10]
Clinical Dosing Evidence: Human studies have used 30–500 mg daily to support quality of life, attention, and cognitive performance in certain populations.*[7,8,9]
Who It’s For
Ideal for adults seeking support for healthy mood, cognitive function, or hormonal balance, especially during periods of stress.*
Special Features
ARG offers Pregnenolone (micronized) for enhanced bioavailability in 50 mg and 100 mg strength options to accommodate individualized, evidence-informed protocols.*
Pregnenolone helps bridge the gap between hormone synthesis and brain health, supporting multiple systems through a foundational neurosteroid pathway.*
Supplement Facts
Serving Size: 1 scored tablet
Servings Per Container: 60
Amount per Serving
Pregnenolone: 50 mg
Other Ingredients
Micosolle® Blend (potassium hydroxide, silicon dioxide, magnesium sulfate heptahydrate, polysorbate 80, citric acid), microcrystalline cellulose, vegetable oil, vegetable wax, Cab-o-sil® (silica), magnesium stearate, vitamin E.
Suggested Use
As a dietary supplement, take 1 tablet daily with a meal, or as directed by a healthcare practitioner.
Warning
NOT FOR USE BY INDIVIDUALS UNDER THE AGE OF 18 YEARS. DO NOT USE IF PREGNANT OR NURSING.
Consult a physician or licensed qualified health care professional before using this product if you have, or have a family history of, prostate cancer, prostate enlargement, heart disease, low "good" cholesterol (HDL), or if you are using any other dietary supplement, prescription drug, or over-the-counter drug. Do not exceed the recommended serving. Exceeding the recommended serving may cause serious adverse health effects. Possible side effects include acne, hair loss, hair growth on the face (in women), aggressiveness, irritability, and increased levels of estrogen. Discontinue use and call a physician or licensed qualified health care professional immediately if you experience rapid heartbeat, dizziness, blurred vision, or other similar symptoms.
Store in a cool, dry place, tightly capped, away from light. Keep out of the reach of children. Use only if the safety seal is intact. Variations in product color may occur.
References
1. Murugan S, et al. J Biol Chem. 2019;294(12):4596–607.
2. Mathis C, et al. Psychopharmacology (Berl). 1994;116(2):201–6.
3. Mathis C, et al. Neuropharmacology. 1996;35(8):1057–64.
4. Pierce SR, et al. Mol Pharmacol. 2022;101(2):68–77.
5. Charalampopoulos I, et al. Ann N Y Acad Sci. 2006;1088:139–52.
6. Vallee M, et al. Brain Res Brain Res Rev. 2001;37(1–3):301–12.
7. Naylor JC, et al. JAMA Netw Open. 2020;3(3):e200287. doi:10.1001/jamanetworkopen.2020.0287
8. Kreinin A, et al. Clin Schizophr Relat Psychoses. 2017;10(4):201–10.
9. Ritsner MS, et al. J Clin Psychiatry. 2010;71(10):1351–62.
10. Naert G, et al. Psychoneuroendocrinology. 2007;32(8–10):1062–78.
